Cost Only

This type of study ignores clinical outcomes and relies exclusively upon the expense of a treatment or strategy. Many newer and more expensive agents improve quality and quantity of life (cetuximab, bevicizimab, irinotecan, or oxaliplatin in metastatic colon cancer; all at $2,000-$4,000 per treatment).6 This type of method is often used by insurers as a rationale to not cover particular medications that may be efficacious but do not have enough supporting data to become a requisite standard of care. Ibritumomab tiuxetan (zevalin), an yttrium-90 antibody to CD20, is an active agent against non-Hodgkins lymphoma (NHL), but may register acute "sticker-shock" effect with many payers at $22,000-$28,000 per dose. And although it appears to have definite activity in NHL, it has not yet evolved into a definitive treatment choice in the algorithm of salvage therapy, at least in part because payers may not reimburse for its use. Unfortunately, cost alone does not help clinicians choose among a variety of therapeutic strategies, unless out-of-pocket expenses for patients make treatment unattainable.

Herbal Remedy Secret Uncovered

Herbal Remedy Secret Uncovered

Discover How To Use Herbal Medicine Effectively To Heal Away Disease amp illnesses That Most Of The Herbalist Do Not Want You To Know About. If You Have Never Know What Is All About Herbal Medicines amp The Correct Way Of Using Herbs To Build A Healthier Life, Then This Guide Is About To Reveal All Just That.

Get My Free Ebook

Post a comment